Ghana, a lower-middle-income country, was the first country to sign a Global Fund grant in 2002. The Global Fund considers Ghana as one of the 20 high "impact countries" worldwide that together
- account for 70% of the worldwide burden of HIV/AIDS, tuberculosis and malaria and
- receive 70% of the value of the Global Fund grants.
Ghana is making robust commitments to increase its domestic investments in health.
Malaria: From 2014-2017, almost 18 million mosquito nets were distributed. The death rate among children under five due to malaria was lowered from 14% in 2000 to less than 1% since 2012.
TB: Over 96,000 new tuberculosis cases have been detected and treated. TB treatment success rates has been high and steady. Multidrug-resistant TB case notification has increased from 4 in 2010 to 200 in 2017.
HIV: In the end of 2017, more than 125,000 people living with HIV (PLHIV) received the life saving antiretroviral treatment. Almost 90% of the pregnant women visiting ANC were tested for HIV and more than 80% of those who tested positive are covered by the prevention of mother-to-child project.
However, more needs to be done. Ghana aims to achieve the 90-90-90 fast-track targets – currently, about 40% of the estimated 315,000 PLHIV are on antiretroviral therapy. In spite of all efforts, TB detection rate is a low 33%. Efforts to provide quality diagnosis and treatment of malaria also need to be sustained. A cross cutting challenge is data quality that needs to be further enhanced as a basis for effective decision making.
Until December 2017, the Global Fund has invested in Ghana